Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

Bristol-Myers Squibb Company BMY reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.67, which beat the ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...